Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection
Section snippets
Background
Chronic hepatitis B virus (HBV) infection remains a serious public health problem affecting more than 400 million people worldwide [1]. According to the natural history, chronic HBV carriers can be presented with various clinical states as inactive HBV carriers, individuals with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB), or with liver cirrhosis [2]. Inactive HBV carriers have low levels of HBV-DNA and normal serum aminotransferase and are at low risk to
Objectives
The aim of this study was to investigate whether serum levels of caspase-generated fragments of CK-18 may provide useful information on the extent of liver injury in various clinical conditions of HBV infection. Furthermore, we explored whether serum M30-antigen level can be used to predict significant necroinflammation in patients with CHB.
Patients
A total of 339 patients with chronic HBV infection were prospectively recruited from 6 medical centers (Ajou University Hospital, Hallym University Chuncheon, CHA University Hospital, Inje University Busan Paik Hospital, Pusan National University Hospital and Catholic University St. Vincent's Hospital) in South Korea from October 2005 to June 2009. All patients underwent liver biopsy and had not received antiviral treatment within 6 months prior to this study's enrollment. Patients were not
Patient characteristics
The baseline characteristics of the enrolled patients are outlined in Table 1. Three hundred and thirty-nine patients (234 men and 105 women) between 18 and 70 years of age (mean, 42.98 ± 18.10 years) were included. The distribution of inflammatory activity grades and fibrosis stages of all patients was as follows: grade 1 = 43 (12.7%), grade 2 = 109 (32.2%), grade 3 = 116 (34.2%) and grade 4 = 71 (20.9%); F0 = 12 (3.5%), F1 = 54 (15.9%), F2 = 100 (29.5%), F3 = 91 (26.8%) and F4 = 82 (24.2%).
M30 antigen levels in different stages of chronic HBV infection
We assessed serum
Discussion
In this study, we evaluated whether serum M30-antigen levels can serve as useful biomarkers of liver necroinflammation in the clinical spectrum of HBV infection. Serum M30 antigen levels were correlated with serum markers of liver inflammation and histologic inflammatory grades in patients with CHB. The mean level of M30-antigen in HBeAg negative CHB patients was significantly higher than that of inactive carriers. Furthermore, a combined analysis of AST and M30-antigen was able to detect
Funding
This work was supported by a grant from the Ministry of Health and Welfare, Republic of Korea (no. A102065).
Competing interests
We declare that we have no conflict of interests.
Ethical approval
The study protocols were approved by the Institutional Review Board of Human Research of Ajou University Hospital (AJIRB-MED-KSP-11-372) and the local research ethics committees at all participating hospitals. Informed consent to participate in the study was obtained from all study subjects.
References (27)
- et al.
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection
Am J Gastroenterol
(2003) - et al.
Keratins: guardians of the liver
Hepatology
(2002) - et al.
Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection
Hepatology
(2001) - et al.
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
Hepatology
(2003) - et al.
Apoptosis and liver disease
Am J Med
(2000) - et al.
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
J Hepatol
(2002) - et al.
Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B
Clin Chim Acta
(2010) - et al.
Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B
Clin Biochem
(2012) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
J Viral Hepat
(2004)The natural history of chronic hepatitis B virus infection
Semin Liver Dis
(2004)
Revision and update on clinical practice guideline for liver cirrhosis
Korean J Hepatol
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment
Semin Liver Dis
Apoptosis in hepatitis C virus infection
Cell Death Differ
Cited by (19)
Efficacy and safety of emricasan in liver cirrhosis and/or Fibrosis
2021, ClinicsCitation Excerpt :There was no heterogeneity among the included studies for all the assessed parameters, with I2=0% (4% for overall AEs) and p-value >0.05 (Figure 5). Progressive chronic liver disorders, including non-alcoholic steatohepatitis (41), hepatitis C (42), hepatitis B (43), and alcoholic liver diseases (43), have all been reported to be correlated with excessive caspase activation and liver cell apoptosis. In this context, caspase inhibitors, particularly pan-caspase inhibitors, have been shown to have a protective effect against hepatocyte injury in animal models of liver failure secondary to alcoholic cirrhosis, fatty liver diseases, and cholestatic liver disease (44–46).
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo
2019, Clinical Gastroenterology and HepatologyCitation Excerpt :Following 6 months of treatment, Emricasan improved total bilirubin (–0.65 mg/dL), INR (–0.21), albumin (+0.1), MELD scores (–2.8), and Child-Pugh scores (–0.7) in subjects with baseline MELD scores ≥15. Chronic progressive liver diseases, such as NASH,1 hepatitis C,3 hepatitis B,4 and alcoholic liver disease,2 are all associated with excessive caspase activation and hepatocyte apoptosis. It was therefore interesting to compare the improvement in liver function observed with treating the result of hepatocyte injury (caspase activation) with directly treating the cause of injury.
Relationship between liver injury and serum cytokeratin 18 levels in asymptomatic hepatitis B virus carriers and in patients with chronic hepatitis B infection
2017, Arab Journal of GastroenterologyCitation Excerpt :Furthermore, another study showed that serum CK18 (M30-antigen) levels were useful in differentiating inactive carriers from patients with HBeAg-negative CHB. The same study also reported that M30-antigen levels correlated well with liver necroinflammation [19]. Zheng et al. [20] also demonstrated that CK18 (M65 and M30) levels were strongly associated with the severity of liver disease.
Serum hepatocyte apoptosis biomarker predicts the presence of significant histological lesion in chronic hepatitis B virus infection
2016, Digestive and Liver DiseaseCitation Excerpt :Further investigation in exploring and validating novel non-invasive biomarkers in assessing histological changes in chronic HBV infection is still urgently needed. More recently, Keratin-18 (K-18) associated fragments have been identified for their ability to predict histological lesions in chronic liver diseases [17–20]. Circulating level of caspase-cleaved K-18 (M30) is exclusively indicative of hepatocytes apoptosis level and full-length K-18 (M65) generally represents the extent of total hepatocytes death in liver diseases [21].
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis
2016, Digestive and Liver DiseaseCitation Excerpt :Conversely, CK18-Asp396 has a high PPV as marker of fibrosis in NAFLD, hence their combination could be useful. Circulating CK18-Asp396 fragments are increased also in liver diseases of different aetiology and have been associated to the extent of both liver fibrosis and steatosis in CHC [15–17] and to degree of necroinflammation in CHB subjects [18]. Transient elastography (FibroScan), a non-invasive method which measures liver stiffness (LS) as a function of the extent of fibrosis [3,19,20], is currently the most used imaging tool for the indirect detection of liver fibrosis and it has been validated in several large-scale prospective studies [21–23].
Emricasan for the treatment of liver cirrhosis: a meta-analysis of randomized controlled trials
2023, African Health Sciences